カテゴリ： GlobalData, イギリス, 企業調査

Hikma Pharmaceuticals Plc (HIK)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Hikma Pharmaceuticals Plc (HIK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10020
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：72
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and Rest of the World (ROW). Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc (HIK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 16
Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 17
Venture Financing 18
Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18
Prognos Health Raises USD20.5 Million in Series C Financing 20
Partnerships 21
Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 21
Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 22
Hikma Pharma Forms Joint Venture With Midroc Pharma 23
Venture Life Enters into Distribution Agreement with Hikma Pharma 24
Licensing Agreements 25
Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 25
Hikma Pharma Enters into Licensing Agreement with Rovi 26
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 27
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 28
Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 29
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 30
Hikma Pharma Enters into Licensing Agreement with Octapharma 31
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 32
Hikma Pharma Enters into Licensing Agreement with Vitabiotics 33
Hikma Pharma Enters into Licensing Agreement with Azanta 34
Hikma Pharma Enters into Licensing Agreement with SK Chemicals 35
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 36
Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 37
Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 38
Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 39
Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 40
Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 41
Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 42
Debt Offering 43
Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43
Asset Transactions 44
Amphastar Pharma Acquires 14 ANDAs from Hikma Pharma for USD4 Million 44
Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 45
Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 46
Acquisition 47
Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 47
Hikma Pharma to Acquire EIMC United Pharma 49
Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 50
Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 52
Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 53
Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For US$42 Million 54
Hikma Pharmaceuticals Plc – Key Competitors 55
Hikma Pharmaceuticals Plc – Key Employees 56
Hikma Pharmaceuticals Plc – Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Joint Venture 58
Recent Developments 59
Financial Announcements 59
Aug 15, 2018: Hikma Pharmaceuticals: Half-year report 59
Mar 14, 2018: Hikma reports 2017 full year results 64
Aug 17, 2017: Hikma Delivers Stable Profitability and Strong Cash Generation In H1 and Maintains a Solid Balance Sheet 65
Mar 15, 2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency 66
Corporate Communications 67
Jun 04, 2018: Hikma Appoints Henriette Nielsen As Chief Transformation Officer 67
Feb 20, 2018: Sigurdur Olafsson appointed Chief Executive Officer of Hikma 68
Jan 15, 2018: Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D 69
Jun 26, 2017: Hikma Pharmaceuticals Announces Leadership and Organisational Changes to US Business 70
Other Significant Developments 71
May 03, 2017: Hikma Changes Registered Office 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hikma Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Hikma Pharma Acquires Six Products from Boehringer Ingelheim 16
Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 17
Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18
Prognos Health Raises USD20.5 Million in Series C Financing 20
Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 21
Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 22
Hikma Pharma Forms Joint Venture With Midroc Pharma 23
Venture Life Enters into Distribution Agreement with Hikma Pharma 24
Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 25
Hikma Pharma Enters into Licensing Agreement with Rovi 26
Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 27
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 28
Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 29
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 30
Hikma Pharma Enters into Licensing Agreement with Octapharma 31
Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 32
Hikma Pharma Enters into Licensing Agreement with Vitabiotics 33
Hikma Pharma Enters into Licensing Agreement with Azanta 34
Hikma Pharma Enters into Licensing Agreement with SK Chemicals 35
Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 36
Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 37
Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 38
Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 39
Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 40
Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 41
Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 42
Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43
Amphastar Pharma Acquires 14 ANDAs from Hikma Pharma for USD4 Million 44
Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 45
Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 46
Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 47
Hikma Pharma to Acquire EIMC United Pharma 49
Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 50
Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 52
Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 53
Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For US$42 Million 54
Hikma Pharmaceuticals Plc, Key Competitors 55
Hikma Pharmaceuticals Plc, Key Employees 56
Hikma Pharmaceuticals Plc, Subsidiaries 57
Hikma Pharmaceuticals Plc, Joint Venture 58

List of Figures
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

★海外企業調査レポート[Hikma Pharmaceuticals Plc (HIK)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Concordia International Rx UK Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Concordia International Rx UK Ltd (Concordia) formerly Amdipharm Mercury Company Ltd, a subsidiary of Concordia International Corp, is a manufacturer of pharmaceutical products and orphan drugs. The company’s products include acetazolamide, adenosine, adrenaline acid tartrate, alfacalcidol, …
  • PTC Inc.：企業の戦略・SWOT・財務情報
    PTC Inc. - Strategy, SWOT and Corporate Finance Report Summary PTC Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • InviCRO LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary InviCRO LLC (InviCRO) a subsidiary of Konica Minolta Inc, is a provider of image informatics, engineering and operational services in translational drug discovery and development. The company developed VivoQuant, a DICOM compliant post-processing suite for image data combining fundamental vi …
  • Yantai Jereh Oilfield Services Group Co Ltd (002353)：石油・ガス：M&Aディール及び事業提携情報
    Summary Yantai Jereh Oilfield Services Group Co Ltd (Yantai Jereh), formerly Yantai Jereh Equipment Group Co Ltd is an integrated oil and gas company that manufactures, designs, and markets oilfield equipment. The company offers oil and gas field equipment such as drilling and workover rig, simulati …
  • Distil plc：企業の戦略・SWOT・財務情報
    Distil plc - Strategy, SWOT and Corporate Finance Report Summary Distil plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Development Bank of Southern Africa：企業の戦略的SWOT分析
    Development Bank of Southern Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Sojitz Corp (2768)：企業の財務・戦略的SWOT分析
    Sojitz Corp (2768) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Nuri Telecom Co., Ltd. (040160)：企業の財務・戦略的SWOT分析
    Nuri Telecom Co., Ltd. (040160) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • China Construction Bank Corp
    China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report Summary China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Usg Corporation
    Usg Corporation - Strategy, SWOT and Corporate Finance Report Summary Usg Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Molecular Health GmbH：製薬・医療：M&Aディール及び事業提携情報
    Summary Molecular Health GmbH (Molecular Health) is a biomedical company that designs, develops, manufactures and commercializes software systems which performs integrated analysis of clinical and genomic patient data to support treatment decisions and provide related services. The company offers Mo …
  • Secom Co Ltd (9735)：企業の財務・戦略的SWOT分析
    Secom Co Ltd (9735) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Sun Pharma Advanced Research Company Ltd (SPARC)：企業の財務・戦略的SWOT分析
    Summary Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd, is a bio pharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatme …
  • The Broad Institute Inc-医療機器分野：企業M&A・提携分析
    Summary The Broad Institute Inc (Broad Institute), a subsidiary of The Broad Foundation is a non-profit research organization that conducts genomic research for treatment of human diseases. The organization transforms medicine by utilizing systematic approaches in biological sciences, to speed up th …
  • Israel Military Industries Ltd.：企業の戦略・SWOT・財務情報
    Israel Military Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Israel Military Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • ET Solar Group Corporation-エネルギー分野：企業M&A・提携分析
    Summary ET Solar Group Corporation (ET Solar) is a provider of renewable energy equipment and services. The company produces a wide variety of photovoltaic (PV) modules based on global standards such as IEC, TUV, VDE, and UL. It also provides horizontally integrated project development; finance and …
  • Asahi Kasei Corp (3407)：製薬・医療：M&Aディール及び事業提携情報
    Summary Asahi Kasei Corp (Asahi Kasei), manufactures, and markets chemical products. The product portfolio of the company includes polymers, acrylonitrile, styrene, diagnostic reagents, foam insulation panels, foundation systems, methyl methacrylate, adipic acid, polyethylene, polystyrene, functiona …
  • Nisshinbo Holdings Inc. (3105)：企業の財務・戦略的SWOT分析
    Nisshinbo Holdings Inc. (3105) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Sandvik AB：企業の戦略・SWOT・財務分析
    Sandvik AB - Strategy, SWOT and Corporate Finance Report Summary Sandvik AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Arotech Corporation：企業の戦略・SWOT・財務分析
    Arotech Corporation - Strategy, SWOT and Corporate Finance Report Summary Arotech Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆